The validation process indicates that the variables MGMT, ADC, age, and edema divided the primary GBM patients into two subgroups with significant differences in the predicted survival patterns (MGMT: P = 0.00154, ADC: P = 0.02874, age: P = 0.00238, edema: P = 0.03998) (Figure 3A‐D). The gene discussed is MGMT; the disease is glioblastoma.